# US 2013/0156840 A1 · Implantable intraocular drug delivery apparatus, system and method > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2013/0156840 A1 - Document ID: US20130156840A1 - Status: Published application - Kind: A1 - Application number: 13/331,005 - Filed: 2011-12-20 - Published: 2013-06-20 - Earliest claimed: 2011-12-20 - Assignees: Abbott Medical Optics Inc. - Inventors: Brooke C. Basinger; Daniel J. Urbaniak - Web page: https://patentgrep.com/patent/US20130156840A1 ## CPC - A61F 9/0017: {implantable in, or in contact with, the eye, e.g. ocular inserts} - A61K 9/0051: {Ocular inserts or implants} - A61P 27/02: Ophthalmic agents - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract The present invention relates to an apparatus, system and method for, and for providing, intraocular delivery of an active agent. The apparatus, system and method may include an implantable scaffold and an active agent associated with the implantable scaffold. The implantable scaffold and the active agent may be configured to be completely contained within the eye upon implantation. The implantable scaffold may be a mechanical scaffold, or the implantable scaffold may be a chemical scaffold. ## Claims ### Claim 1 An intraocular active agent delivery system, comprising: an implantable scaffold; and an active agent at least physically associated with said implantable scaffold, wherein said implantable scaffold and said active agent are configured to be completely contained within an eye upon implantation. ### Claim 2 (depends on 1) The system of claim 1, wherein the implantable scaffold comprises a mechanical scaffold. ### Claim 3 (depends on 2) The system of claim 2, wherein the implantable scaffold is generally in the shape of a ring. ### Claim 4 (depends on 2) The system of claim 2, wherein the implantable scaffold is generally in the shape of a cylinder prior to implantation. ### Claim 5 (depends on 2) The system of claim 2, wherein the implantable scaffold comprises a reservoir. ### Claim 6 (depends on 5) The system of claim 5, wherein the reservoir releasably contains at least a portion of the active agent. ### Claim 7 (depends on 6) The system of claim 6, wherein the reservoir is configured to be refilled. ### Claim 8 (depends on 1) The system of claim 1, wherein the implantable scaffold comprises a coating comprising at least a portion of the active agent. ### Claim 9 (depends on 8) The system of claim 8, wherein at least some of the active agent is configured to be time-released from the coating. ### Claim 10 (depends on 1) The system of claim 1, wherein the active agent is delivered over a period of at least 6 months. ### Claim 11 (depends on 1) The system of claim 1, wherein the active agent is delivered over a period of at least 1 year. ### Claim 12 (depends on 1) The system of claim 1, wherein the implantable scaffold comprises a chemical scaffold. ### Claim 13 (depends on 12) The system of claim 12, wherein the chemical scaffold comprises a polymeric gel. ### Claim 14 (depends on 13) The system of claim 13, wherein the polymeric gel comprises a polysaccharide. ### Claim 15 (depends on 13) The system of claim 13, wherein the active agent is released from the polymeric gel upon degradation of the polymeric gel. ### Claim 16 (depends on 12) The system of claim 12, wherein the active agent is connected to the chemical scaffold by covalent bonding. ### Claim 17 (depends on 12) The system of claim 12, wherein the active agent is connected to the chemical scaffold by ionic coupling. ### Claim 18 (depends on 12) The system of claim 12, wherein the active agent is covalently bonded to the chemical scaffold by carboxylate esterification, hydroxyl esterification, phosphate esterification, amide bonding, or a combination thereof. ### Claim 19 (depends on 12) The system of claim 12, wherein the active agent is ionically coupled to the chemical scaffold. ### Claim 20 (depends on 14) The system of claim 14, wherein the polysaccharide has an average molecular weight of 700 kDa or greater. ### Claim 21 (depends on 14) The system of claim 14, wherein the polysaccharide has an average molecular weight of 1000 kDa or greater. ### Claim 22 (depends on 14) The system of claim 14, wherein at least two polysaccharides are cross-linked through carboxylic acid groups. ### Claim 23 (depends on 14) The system of claim 14, wherein at least two polysaccharides are cross-linked through hydroxyl groups. ### Claim 24 An implantable scaffold suitable for intraocular delivery of at least one active agent, comprising: at least one vehicle suitable for intraocular implantation; and at least one physical association of the at least one active agent with said at least one vehicle, wherein said at least one physical association is suitable for intraocular delivery of the at least one active agent by said at least one vehicle upon the intraocular implantation of at least said at least one vehicle, said physical association, and the at least one active agent. ### Claim 25 A method of providing intraocular delivery of an active agent, comprising: providing a scaffold suitable for intraocular implantation; associating the active agent with the scaffold; providing for the delivery of the active agent from the scaffold following the intraocular implantation, wherein the active agent is delivered following the intraocular implantation. ### Claim 26 (depends on 25) The method of claim 25, wherein said associating comprises mechanically associating. ### Claim 27 (depends on 26) The method of claim 26, wherein said mechanically associating comprises filling at least a portion of the scaffold with the active agent. ### Claim 28 (depends on 27) The method of claim 27, wherein the delivery includes at least release of the active agent from the filled portion of the scaffold. ### Claim 29 (depends on 25) The method of claim 25, wherein said associating comprises chemically associating.